<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01235338</url>
  </required_header>
  <id_info>
    <org_study_id>SPD489-117</org_study_id>
    <nct_id>NCT01235338</nct_id>
  </id_info>
  <brief_title>Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Open-label, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of SPD489 and EFFEXOR XR, Administered Alone and in Combination in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effects of co-administration of SPD489 and the antidepressant
      EFFEXOR XR on the pharmacokinetics of lisdexamfetamine, d-amphetamine, and EFFEXOR XR. In
      addition, serial blood pressure and pulse measures will be obtained and examined to ensure
      that there are no unexpected changes in vital signs following co administration of SPD489 and
      EFFEXOR XR that would impact the further study of this drug combination. The hypothesis is
      that a drug drug interaction could possibly exist.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate</measure>
    <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
    <description>Lisdexamfetamine dimesylate (SPD489) itself is inactive, but following oral administration is converted to the active isomer, d-amphetamine, that is responsible for the drug's therapeutic activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of d-Amphetamine</measure>
    <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
    <description>d-Amphetamine is the active isomer of Lisdexamfetamine dimesylate (SPD489) and is responsible for the drug's therapeutic activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Venlafaxine Hydrochloride</measure>
    <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
    <description>Venlafaxine Hydrochloride is the active ingredient of Effexor XR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of o-Desmethylvenlafaxine</measure>
    <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
    <description>Venlafaxine, after oral administration, is metabolized in the liver to an active metabolite, o-Desmethylvenlafaxine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Composite (Venlafaxine + o-Desmethylvenlafaxine)</measure>
    <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate</measure>
    <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of d-Amphetamine</measure>
    <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of Venlafaxine Hydrochloride</measure>
    <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of o-Desmethylvenlafaxine</measure>
    <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of Composite (Venlafaxine + o-Desmethylvenlafaxine)</measure>
    <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Maximum Plasma Concentration (Tmax) of Lisdexamfetamine Dimesylate</measure>
    <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of d-Amphetamine</measure>
    <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Venlafaxine Hydrochloride</measure>
    <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of o-Desmethylvenlafaxine</measure>
    <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Composite (Venlafaxine + o-Desmethylvenlafaxine)</measure>
    <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>Baseline and up to 39 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>Baseline and up to 39 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Rate</measure>
    <time_frame>Baseline and up to 39 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LDX (SPD489) + Venlafaxine XR (Effexor XR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Venlafaxine XR + LDX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDX + Venlafaxine XR</intervention_name>
    <description>Day 1-5 LDX 30mg
Day 6-10 LDX 50mg
Day 11-15 LDX 70mg
Day 16-20 LDX 70mg and Venlafaxine XR 75mg daily
Day 21-25 LDX 70mg and Venlafaxine XR 150mg daily
Day 26-30 LDX 70mg and Venlafaxine XR 225mg daily
Day 31-34 Venlafaxine XR 150mg daily
Day 35-38 Venlafaxine XR 75mg daily.</description>
    <arm_group_label>LDX (SPD489) + Venlafaxine XR (Effexor XR)</arm_group_label>
    <other_name>Lisdexamfetamine dimesylate, LDX, Vyvanse, SPD489; Venlafaxine hydrochloride extended-release, Effexor XR,</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine XR + LDX</intervention_name>
    <description>Day 1-5 Venlafaxine XR 75mg
Day 6-10 Venlafaxine XR 150mg
Day 11-15 Venlafaxine XR 225mg
Day 16-20 Venlafaxine XR 225mg and LDX 30mg daily
Day 21-25 Venlafaxine XR and LDX 50mg daily
Day 26-30 Venlafaxine XR 225mg and LDX 70mg daily
Day 31-34 Venlafaxine XR 150mg
Day 35-38 Venlafaxine XR 75mg.</description>
    <arm_group_label>Venlafaxine XR + LDX</arm_group_label>
    <other_name>Venlafaxine hydrochloride extended-release, Effexor XR; Lisdexamfetamine dimesylate, LDX, Vyvanse, SPD489</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-45 years

          2. Subject is willing to comply with any applicable contraceptive requirements of the
             protocol and is:

               -  Male, or

               -  Non-pregnant, non-lactating female

               -  Females must be at least 90 days post partum or nulliparous.

          3. Female subjects must have a negative serum beta Human Chorionic Gonadotropin (HCG)
             pregnancy test

          4. Satisfactory medical assessment

          5. Ability to provide information on family history of hypertension.

          6. Body Mass Index (BMI) between 18.5 and 30.0kg/mÂ² inclusive.

          7. Ability to swallow all investigational products.

        Exclusion Criteria:

          1. Current or recurrent disease (e.g., cardiovascular, renal, liver, gastrointestinal,
             malignancy or other conditions)

          2. Current or relevant previous history of physical or psychiatric illness.

          3. Significant illness.

          4. History of significant anxiety, tension, or agitation as assessed by the Investigator.

          5. History of or current diagnosis of glaucoma.

          6. History of a seizure disorder (other than infantile febrile seizures), any tic
             disorder or a current diagnosis and/or known family history of Tourette's Disorder.

          7. History of symptomatic cardiovascular disease, advanced arteriosclerosis, structural
             cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary
             artery disease, transient ischemic attack or stroke, or other serious cardiac
             problems.

          8. History of controlled or uncontrolled hypertension or a resting sitting systolic BP
             &gt;139mmHg or diastolic BP &gt;89mmHg.

          9. Known family history of sudden cardiac death or ventricular arrhythmia.

         10. Suicidal ideation or any lifetime history of suicidal behavior.

         11. Consumption of alcohol, Seville oranges, grapefruit, or any grapefruit containing
             products within 7 days of first dose of investigational product.

         12. Current use of any medication (including prescription, over the counter [OTC], herbal
             or homeopathic preparations or supplements) with the exception of the occasional dose
             of acetaminophen, or hormonal contraceptives.

         13. History of alcohol or other substance abuse within the last year.

         14. A positive screen for alcohol or drugs of abuse.

         15. Male subjects who consume more than 21 units of alcohol per week or 3 units per day.
             Female subjects who consume more than 14 units of alcohol per week or 2 units per day.
             [1 alcohol unit =1 beer = 1 wine (5oz) = 1 liquor (1.5oz) = 0.75oz alcohol]

         16. A positive human immunodeficiency virus (HIV) antibody screen, Hepatitis B surface
             antigen (HBsAg), or Hepatitis C virus (HCV) antibody screen.

         17. Use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing
             products in any form (e.g. gum, patch). Ex-users must report that they have stopped
             using tobacco for at least 30 days prior to receiving the first dose of
             investigational product.

         18. Routine consumption of more than 2 units of caffeine per day or subjects who
             experience caffeine withdrawal headaches. (One caffeine unit is contained in the
             following items: one 6oz. cup of coffee, two 12oz. cans of cola, one 12oz. cup of tea,
             three 1oz. chocolate bars, or one 8oz. serving of an energy drink. Decaffeinated
             coffee, tea, or cola are not considered to contain caffeine).

         19. Donation of blood or blood products (e.g., plasma or platelets) within 60 days prior
             to receiving the first dose of investigational product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>FDA Recall Information</description>
  </link>
  <results_reference>
    <citation>Ermer J, Haffey MB, Richards C, Lasseter K, Roesch B, Purkayastha J, Corcoran M, Harlin B, Martin P. An open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults. Clin Drug Investig. 2013 Apr;33(4):243-54. doi: 10.1007/s40261-013-0073-1.</citation>
    <PMID>23512639</PMID>
  </results_reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2010</study_first_posted>
  <results_first_submitted>November 4, 2011</results_first_submitted>
  <results_first_submitted_qc>November 4, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 8, 2011</results_first_posted>
  <last_update_submitted>March 27, 2013</last_update_submitted>
  <last_update_submitted_qc>March 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 80 randomized subjects, 3 did not receive any investigational product and therefore were not included in the Safety Analysis/Pharmacokinetic Analysis Sets (n = 77).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LDX + Venlafaxine XR</title>
          <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
        </group>
        <group group_id="P2">
          <title>Venlafaxine XR + LDX</title>
          <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Exclusion criteria violations</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Positive drug screen</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prohibited meds</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LDX + Venlafaxine XR</title>
          <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
        </group>
        <group group_id="B2">
          <title>Venlafaxine XR + LDX</title>
          <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>The Safety Analysis Set (n = 77) was used to calculate Baseline Measures. The Safety Analysis Set is defined as all enrolled subjects who took at least 1 dose of investigational product and had at least 1 post-dose safety assessment. 80 subjects were enrolled but 3 never received investigational product.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.2" spread="7.01"/>
                    <measurement group_id="B2" value="33.8" spread="7.29"/>
                    <measurement group_id="B3" value="33.5" spread="7.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 18 and 45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate</title>
        <description>Lisdexamfetamine dimesylate (SPD489) itself is inactive, but following oral administration is converted to the active isomer, d-amphetamine, that is responsible for the drug's therapeutic activity.</description>
        <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
        <population>Pharmacokinetic Analysis Set (PAS) defined as all subjects who took a t least 1 dose of investigational product and had at least 1 post-dose safety assessment and who had no major deviations related to investigational product intake (e.g. vomiting) and for whom the primary pharmacokinetic data were considered sufficient and interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>LDX + Venlafaxine XR</title>
            <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR + LDX</title>
            <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate</title>
          <description>Lisdexamfetamine dimesylate (SPD489) itself is inactive, but following oral administration is converted to the active isomer, d-amphetamine, that is responsible for the drug's therapeutic activity.</description>
          <population>Pharmacokinetic Analysis Set (PAS) defined as all subjects who took a t least 1 dose of investigational product and had at least 1 post-dose safety assessment and who had no major deviations related to investigational product intake (e.g. vomiting) and for whom the primary pharmacokinetic data were considered sufficient and interpretable.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.06" spread="32.25"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.84" spread="34.3"/>
                    <measurement group_id="O2" value="50.77" spread="19.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of d-Amphetamine</title>
        <description>d-Amphetamine is the active isomer of Lisdexamfetamine dimesylate (SPD489) and is responsible for the drug's therapeutic activity.</description>
        <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>LDX + Venlafaxine XR</title>
            <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR + LDX</title>
            <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of d-Amphetamine</title>
          <description>d-Amphetamine is the active isomer of Lisdexamfetamine dimesylate (SPD489) and is responsible for the drug's therapeutic activity.</description>
          <population>PAS</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.91" spread="26.87"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.91" spread="22.72"/>
                    <measurement group_id="O2" value="85.27" spread="20.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Venlafaxine Hydrochloride</title>
        <description>Venlafaxine Hydrochloride is the active ingredient of Effexor XR</description>
        <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>LDX + Venlafaxine XR</title>
            <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR + LDX</title>
            <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Venlafaxine Hydrochloride</title>
          <description>Venlafaxine Hydrochloride is the active ingredient of Effexor XR</description>
          <population>PAS</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="210.98" spread="120.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198.5" spread="105.48"/>
                    <measurement group_id="O2" value="228.89" spread="124.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <time_frame>Baseline and up to 39 days</time_frame>
        <population>Safety Analysis Set (SAS) defined as all enrolled subjects who took at least 1 dose of investigational product and had at least 1 post-dose safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>LDX + Venlafaxine XR</title>
            <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR + LDX</title>
            <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <population>Safety Analysis Set (SAS) defined as all enrolled subjects who took at least 1 dose of investigational product and had at least 1 post-dose safety assessment.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.17" spread="8.996"/>
                    <measurement group_id="O2" value="110.48" spread="9.623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 39 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.82" spread="8.547"/>
                    <measurement group_id="O2" value="121.51" spread="7.695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure</title>
        <time_frame>Baseline and up to 39 days</time_frame>
        <population>SAS</population>
        <group_list>
          <group group_id="O1">
            <title>LDX + Venlafaxine XR</title>
            <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR + LDX</title>
            <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <population>SAS</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.69" spread="7.446"/>
                    <measurement group_id="O2" value="73.68" spread="6.730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 39 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.85" spread="6.628"/>
                    <measurement group_id="O2" value="80.45" spread="7.4515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of o-Desmethylvenlafaxine</title>
        <description>Venlafaxine, after oral administration, is metabolized in the liver to an active metabolite, o-Desmethylvenlafaxine.</description>
        <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>LDX + Venlafaxine XR</title>
            <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR + LDX</title>
            <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of o-Desmethylvenlafaxine</title>
          <description>Venlafaxine, after oral administration, is metabolized in the liver to an active metabolite, o-Desmethylvenlafaxine.</description>
          <population>PAS</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="420.55" spread="139.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413.71" spread="149.97"/>
                    <measurement group_id="O2" value="371.54" spread="104.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Composite (Venlafaxine + o-Desmethylvenlafaxine)</title>
        <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>LDX + Venlafaxine XR</title>
            <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR + LDX</title>
            <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Composite (Venlafaxine + o-Desmethylvenlafaxine)</title>
          <population>PAS</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="624.56" spread="179.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="603.49" spread="181.32"/>
                    <measurement group_id="O2" value="588.68" spread="158.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate</title>
        <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>LDX + Venlafaxine XR</title>
            <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR + LDX</title>
            <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate</title>
          <population>PAS</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.5" spread="44.0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9" spread="43.7"/>
                    <measurement group_id="O2" value="60.8" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC of d-Amphetamine</title>
        <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>LDX + Venlafaxine XR</title>
            <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR + LDX</title>
            <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of d-Amphetamine</title>
          <population>PAS</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1143.4" spread="292.8"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1135.4" spread="301.5"/>
                    <measurement group_id="O2" value="1049.2" spread="268.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC of Venlafaxine Hydrochloride</title>
        <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>LDX + Venlafaxine XR</title>
            <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR + LDX</title>
            <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of Venlafaxine Hydrochloride</title>
          <population>PAS</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="2900.0" spread="1919.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2839.7" spread="1706.8"/>
                    <measurement group_id="O2" value="3202.6" spread="1942.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC of o-Desmethylvenlafaxine</title>
        <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>LDX + Venlafaxine XR</title>
            <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR + LDX</title>
            <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of o-Desmethylvenlafaxine</title>
          <population>PAS</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="8363.3" spread="2168.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8061.3" spread="2868.7"/>
                    <measurement group_id="O2" value="6955.1" spread="1962.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC of Composite (Venlafaxine + o-Desmethylvenlafaxine)</title>
        <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>LDX + Venlafaxine XR</title>
            <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR + LDX</title>
            <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of Composite (Venlafaxine + o-Desmethylvenlafaxine)</title>
          <population>PAS</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="10738.0" spread="3273.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10673.9" spread="3035.7"/>
                    <measurement group_id="O2" value="10342.2" spread="3096.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Maximum Plasma Concentration (Tmax) of Lisdexamfetamine Dimesylate</title>
        <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>LDX + Venlafaxine XR</title>
            <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR + LDX</title>
            <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Plasma Concentration (Tmax) of Lisdexamfetamine Dimesylate</title>
          <population>PAS</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.3"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.3"/>
                    <measurement group_id="O2" value="1.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of d-Amphetamine</title>
        <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>LDX + Venlafaxine XR</title>
            <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR + LDX</title>
            <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of d-Amphetamine</title>
          <population>PAS</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.5"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.0"/>
                    <measurement group_id="O2" value="3.1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Venlafaxine Hydrochloride</title>
        <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>LDX + Venlafaxine XR</title>
            <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR + LDX</title>
            <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Venlafaxine Hydrochloride</title>
          <population>PAS</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="6.4" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="1.3"/>
                    <measurement group_id="O2" value="5.9" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of o-Desmethylvenlafaxine</title>
        <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>LDX + Venlafaxine XR</title>
            <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR + LDX</title>
            <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of o-Desmethylvenlafaxine</title>
          <population>PAS</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="7.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="1.7"/>
                    <measurement group_id="O2" value="7.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Composite (Venlafaxine + o-Desmethylvenlafaxine)</title>
        <time_frame>Day 15 and Day 30 (24 hour sampling)</time_frame>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>LDX + Venlafaxine XR</title>
            <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR + LDX</title>
            <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Composite (Venlafaxine + o-Desmethylvenlafaxine)</title>
          <population>PAS</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="7.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="1.4"/>
                    <measurement group_id="O2" value="7.0" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse Rate</title>
        <time_frame>Baseline and up to 39 days</time_frame>
        <population>SAS</population>
        <group_list>
          <group group_id="O1">
            <title>LDX + Venlafaxine XR</title>
            <description>LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg once daily (QD) Days 1-5, then LDX 50 mg QD Days 6-10, then LDX 70 mg QD Days 11-15, then LDX 70 mg + venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 16-20, then LDX 70 mg + venlafaxine XR 150 mg QD Days 21-25, then LDX 70 mg + venlafaxine XR 225 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR + LDX</title>
            <description>Venlafaxine XR (Venlafaxine Hydrochloride extended-release, EffexorÂ® XR) 75 mg QD Days 1-5, then venlafaxine XR 150 mg QD Days 6-10, then venlafaxine XR 225 mg QD Days 11-15, then venlafaxine XR 225 mg + LDX (Lisdexamfetamine Dimesylate, SPD489, VyvanseÂ®) 30 mg QD Days 16-20, then venlafaxine XR 225 mg + LDX 50 mg QD Days 21-25, then venlafaxine XR 225 mg + LDX 70 mg QD Days 26-30, then venlafaxine XR 150 mg QD Days 31-34, then venlafaxine XR 75 mg QD Days 35-38.</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse Rate</title>
          <population>SAS</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.24" spread="7.940"/>
                    <measurement group_id="O2" value="66.55" spread="10.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 39 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.47" spread="8.621"/>
                    <measurement group_id="O2" value="81.72" spread="7.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LDX (SPD489)</title>
          <description>Titration dosing period</description>
        </group>
        <group group_id="E2">
          <title>LDX + Venlafaxine XR/Venlafaxine XR + LDX</title>
          <description>Combination dosing periods</description>
        </group>
        <group group_id="E3">
          <title>Venlafaxine XR Titration</title>
          <description>Titration dosing period (Effexor XR 75, 150, and 225 mg)</description>
        </group>
        <group group_id="E4">
          <title>Venlafaxine XR Tapering</title>
          <description>Tapering dosing period (Effexor XR 150 and 75 mg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="67"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Stomach Discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="67"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Euphoric Mood</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Libido Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Hesitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Patrick Martin, MD</name_or_title>
      <organization>Shire Pharmaceutical</organization>
      <email>pmartin@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

